Business Wire

Market Research Proves Success of Galderma’s Harmony Programme for Aesthetic Practice

Del

Market research concludes that Galderma’s Harmony Programme for aesthetic Health Care Professionals (HCPs) significantly increases patient satisfaction. Using Harmony resulted in more returning patients and led to an increase in full face treatments. The research results show how Harmony raises both treatment standards and value in aesthetic practices.

The Harmony programme allows HCPs to spend more time with patients, better understand and define their requests, and as a result, better respond to their expressed needs. Through Harmony, 82% of patients request full face treatment as compared to 63% pre-Harmony. 1

Harmony – Proven Consultation Programme for Aesthetic Practitioners
The Harmony Programme is the first of its kind in aesthetic patient management and now the first to show measured success by research. This new market report demonstrates overall patient satisfaction levels increased from 65% to 85% after the implementation of the Harmony Programme. 1

Galderma developed The Harmony Programme as a comprehensive aesthetic consultation tool for structured, stepwise patient management to encourage dialogue between the practitioner and the patient, increasing patient awareness of the multiple needs that can be served with full face treatment options,” explains Ophélie Massaroni, Global Harmony Programme Manager, Galderma.

A High-Quality Consultation Framework to Grow Aesthetic Practices
The Harmony Programme has also enabled practitioners to increase retention from 53% to 73%.1 For Dr. Ravi Jain, Aesthetic Practitioner, Riverbanks Clinic (Harpenden, UK), “Harmony provides the practitioner a consistent high quality consultation framework. The patients are happier, they opt in for more combination treatments, and they refer more friends to us.”

The research demonstrates that with Harmony 51% of patients now receive a combination of facial injectable treatments, compared to 34% without the Harmony approach. 1

According to Ophélie Massaroni, “The Harmony Programme facilitates the development of a cost-effective personalized treatment plan for each patient. This creates value for money, as a satisfied patient will be more likely to continue with other treatments.” The research revealed the average patient spend increased by 48% following assessment with Harmony. 1

Higher Practitioner and Patient Satisfaction with Harmony
Dr. Jain continues, “Harmony provides a framework where we can go over their original consultation, making it easier to schedule future treatments. More importantly, Harmony allows the patient to participate in their own treatment plan.” Satisfaction with Harmony remains high after 12 months of implementation with 14 out of 15 practitioners likely to both recommend the programme and continue using it in their practice. 1

About Galderma
Galderma, Nestlé Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

About Harmony
The Harmony Programme is a patient management programme developed for leading Health Care Practitioners to master patient consultation. Launched in 2014, Harmony was designed in association with an international multidisciplinary panel of experts. It provides a novel stepwise patient assessment and management method including a suite of sophisticated tools for assessment, facial analysis, and treatment plan follow-up.
http://www.restylane.com/Treatments/Treatment-step-by-step/

References:
1. VIPP Market Research by Research Partnership: Pre-Harmony, Post-Harmony 6-months; Post-Harmony 12-months. 2016.

Contact information

For additional information:
Galderma
Mårten Forrest, +46 768 98 1106
Head of PR & Communication
Aesthetic & Corrective Business
marten.forrest@galderma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13Pressemelding

Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712

Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21Pressemelding

Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr

Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38Pressemelding

A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L

Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00Pressemelding

Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a

AML BitCoin Enters Phase II of ICO15.12.2017 09:00Pressemelding

NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom